Fuyuan Pharmaceutical (601089.SH): Upadacitinib Extended-Release Tablets Obtain Drug Registration Certificate

Zhitong Finance APP news, Fuyuan Pharmaceutical (601089.SH) announced that recently, the company received the "Drug Registration Certificate" issued by the National Medical Products Administration for Upadacitinib Sustained-release Tablets [specification: 15mg (calculated as CHFNO)], approving the production of this drug.